Mild cognitive impairment (MCI)

By Mayo Clinic Staff
Oct. 24, 2024

Research

Publications

See a list of publications about mild cognitive impairment by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Researchers at Mayo Clinic's campuses in Arizona, Florida and Minnesota study risk factors, predictors, prevention, diagnostic techniques and potential treatments for mild cognitive impairment, Alzheimer's disease and other conditions that affect memory and thinking skills. Staff in the Robert and Arlene Kogod Center on Aging also conducts research on many age-related conditions.

The Alzheimer's Disease Research Center at Mayo Clinic's campuses in Florida and Minnesota are two of the more than 30 Alzheimer's disease centers in the United States designated and funded by the National Institute on Aging at the National Institutes of Health. Mayo Clinic's campus in Arizona is part of the Arizona Alzheimer's Consortium, a statewide research collaboration. You may have the opportunity to participate in clinical trials at Mayo Clinic.

  1. Knopman DS, et al. Alzheimer disease. Nature Reviews. Disease Primers. 2021; doi:10.1038/s41572-021-00269-y.
  2. Jankovic J, et al., eds. Alzheimer disease and other dementias. In: Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Sept. 21, 2022.
  3. Zhuang L, et al. Cognitive assessment tools for mild cognitive impairment screening. Journal of Neurology. 2021; doi:10.1007/s00415-019-09506-7.
  4. What is mild cognitive impairment? National Institute on Aging. https://www.nia.nih.gov/health/what-mild-cognitive-impairment. Accessed Aug. 29, 2024.
  5. Mild cognitive impairment (MCI). Alzheimer's Association. https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment. Accessed Aug. 29, 2024.
  6. Lewis JE, et al. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research. 2021; doi:10.18053/jctres.07.202104.014.
  7. Kellerman RD, et al. Alzheimer's disease. In: Conn's Current Therapy 2022. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 29, 2024.
  8. Ferri FF. Mild cognitive impairment. In: Ferri's Clinical Advisor 2023. Elsevier; 2023. https://www.clinicalkey.com. Accessed Aug. 29, 2024.
  9. Petersen RC, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; doi:10.1212/WNL.0000000000004826.
  10. Budson AE, et al. Memory Loss, Alzheimer's Disease, and Dementia. 3rd ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 29, 2024.
  11. Cognitive impairment in older adults: Screening. U.S. Preventive Services Task Force recommendation statement. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cognitive-impairment-in-older-adults-screening. Accessed Aug. 29, 2024.
  12. Petersen RC. Mild cognitive impairment: Epidemiology, pathology, and clinical assessment. https://www.uptodate.com/contents/search. Accessed Aug. 29, 2024.
  13. Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. The Lancet. 2024; doi:10.1016/S0140-6736(24)01296-0.
  14. Cummings J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimer's and Dementia. 2022; doi:10.1002/trc2.12295.
  15. Memory, forgetfulness and aging: What's normal and what's not? National Institute on Aging. https://www.nia.nih.gov/health/memory-forgetfulness-and-aging-whats-normal-and-whats-not. Accessed Aug. 29, 2024.
  16. Jack CR Jr., et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia. 2024; doi:10.1002/alz.13859.
  17. Alzheimer's disease research centers. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-disease-research-centers#minnesota. Accessed Aug. 23, 2024.
  18. About the Alzheimer's Consortium. Arizona Alzheimer's Consortium. https://azalz.org/about/#institutes. Accessed Aug. 23, 2024.
  19. Shi M, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: A focus on aducanumab and lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
  20. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Sept. 23, 2024.
  21. 2024 Alzheimer's disease facts and figures. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/facts-figures. Accessed Aug. 26, 2024.
  22. Halter JB, et al., eds. Cognitive changes in normal and pathologic aging. In: Hazzard's Geriatric Medicine and Gerontology. 8th ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed Sept. 17, 2024.
  23. Proton pump inhibitors. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 8, 2024.
  24. Kang C. Donanemab: First approval. Drugs. 2024; doi:10.1007/s40265-024-02087-4.
  25. Donanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.
  26. Lecanemab injection. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed Sept. 6, 2024.